Long-Term Treatment of Hyperphosphatemia With Bixalomer in Japanese Hemodialysis Patients

Therapeutic Apheresis and Dialysis

Volumn 17, Issue 6, 2013, Pages 612-619

  Akizawa, Tadao ^a   Kameoka, Chisato ^b   Kaneko, Yuichiro ^b   Kawasaki, Shigenori ^b  

^a SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ASTELLAS PHARMA INC   (Japan)

Author keywords

Bixalomer; Chronic kidney disease; Hemodialysis; Hyperphosphatemia

Indexed keywords

BICARBONATE; BIXALOMER; CALCIUM; CALCIUM CARBONATE; CHOLESTEROL; CINACALCET; LANTHANUM CARBONATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PARATHYROID HORMONE; PHOSPHATE; SEVELAMER; VITAMIN D DERIVATIVE;

ABDOMINAL DISCOMFORT; ACUTE CHOLECYSTITIS; ADULT; ARTICLE; BICARBONATE BLOOD LEVEL; BLOOD PH; CALCIUM BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CONSTIPATION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS ULCER; FEMALE; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; INCIDENCE; INTESTINE DIVERTICULOSIS; ISCHEMIC COLITIS; JAPANESE; LICHEN PLANUS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; METABOLIC ACIDOSIS; MULTICENTER STUDY; PARATHYROID HORMONE BLOOD LEVEL; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

BIXALOMER; CHRONIC KIDNEY DISEASE; HEMODIALYSIS; HYPERPHOSPHATEMIA;

AGED; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; HYPERPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PHOSPHATES; PHOSPHORUS; POLYAMINES; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 84890136859     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/1744-9987.12023     Document Type: Article

References (16)

1. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218.
2. Noordzij M, Cranenburg EM, Engelsman LF etal. Progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients. Nephrol Dial Transplant 2011;26:1662-1669.
3. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca×PO (4)product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-2138.
4. Young EW, Albert JM, Satayathum S etal. Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Pattern Study. Kidney Int 2005;67:1179-1187.
5. Floege J, Kim J, Ireland E etal. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011;26:1948-1955.
6. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010;362:1312-1324.
7. Kakuta H, Taniguchi K, Sakaguchi H etal. Studies on the physicochemical characteristic of polymer mixed with water at the ratio of dosage and administration given to patients. Jpn J Clin Dial 2012;28:115-120. (in Japanese).
8. Guideline Working Group, Japanese Society for Dialysis Therapy. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 2008;12:514-525.
9. Payne RB, Little AJ, Williams RB, Milner JR. Interpretation of serum calcium levels in patients with abnormal serum proteins. Br Med J 1973;4:643-646.
10. Japanese Society for Dialysis Therapy. An overview of regular dialysis treatment in Japan as of Dec. 31, 2010. 2011.
11. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-252.
12. Hyodo T, Taira T, Yamamoto S etal. The experience of the administration of sevelamer hydrochloride to the hemodialysis patients (1): How to overcome the constipation as the adverse effect of sevelamer hydrochloride. Jpn J Urol Surg 2005;18:239-247.
13. Brezina B, Qunibi WY, Nolan CR. Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int 2004;66(Suppl 90):S39-45.
14. Slatopolsky E, Liapis H, Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 2005;68:2809-2813.
15. Behets GJ, Verberckmoes SC, Oste L etal. Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 2005;67:1830-1836.
16. Akizawa T, Origasa H, Kameoka C etal. Randomized Controlled Trial of Bixalomer Versus Sevelamer Hydrochloride in Hemodialysis Patients With Hyperphosphatemia [ASN Kidney week 2011 abstract FR-PO1669]. 2011.